WO2026146530 - ATORVASTATIN ORAL SUSPENSION WITH IMPROVED STABILITY AND A METHOD FOR THE PRODUCTION THEREOF
National phase entry is expected:
Publication Number
WO/2026/146530
Publication Date
09.07.2026
International Application No.
PCT/IN2025/052157
International Filing Date
29.12.2025
Title **
[English]
ATORVASTATIN ORAL SUSPENSION WITH IMPROVED STABILITY AND A METHOD FOR THE PRODUCTION THEREOF
[French]
SUSPENSION ORALE D'ATORVASTATINE À STABILITÉ AMÉLIORÉE ET UN DE SES PROCÉDÉS DE PRODUCTION
Applicants **
WOCKHARDT LIMITED
Inventors
SEETHARAMAN, Sritharan
MHASE, Sunil
JENA, Nitishkumar
DUBE, Amol
JAJJAR, Rajeshkumar
Priority Data
202421104453
30.12.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1969 | |
| EPO | Filing, Examination, Granting | 11440 | |
| Japan | Filing, Examination, Granting | 2057 | |
| South Korea | Filing, Examination, Granting | 1851 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,057
Contact Us
Abstract[English]
A stable oral suspension composition of Atorvastatin comprising 0.41% w/v of Atorvastatin calcium trihydrate, 0.20% w/v of Carmellose sodium, 0.60% w/v of Magnesium aluminum silicate, 0.3% w/v of parabens, 0.30% w/v of Sucralose, 0.10% w/v of Acesulfame potassium, 0.30% w/v of Orange flavour and Water. A process for the preparation of said suspension composition is also disclosed.[French]
L'invention concerne une composition de suspension orale stable d'atorvastatine comprenant 0,41 % p/v d'atorvastatine calcique trihydrate, 0,20 % p/v de carmellose sodique, 0,60 % p/v de silicate de magnésium et d'aluminium, 0,3 % p/v de parabènes, 0,30 % p/v de sucralose, 0,10 % p/v d'acésulfame potassium, 0,30 % p/v d'arôme orange et de l'eau. L'invention divulgue également un procédé de préparation de ladite composition de suspension.